XML 83 R72.htm IDEA: XBRL DOCUMENT
v3.20.2

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 10,872 | $ 11,760 | $ 22,929 | $ 22,575
Proceeds from Sale of Intangible Assets |  |  | 85 | 15
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10,780 | 11,632 | 22,671 | 22,359
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 128 | 258 | 216
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,634 | 5,193 | 9,771 | 9,748
United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,612 | 5,189 | 9,733 | 9,736
United States | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 22 | 4 | 38 | 12
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,238 | 6,567 | 13,158 | 12,828
International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,168 | 6,442 | 12,938 | 12,622
International | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 125 | 220 | 206
Total Pharmaceutical segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 9,679 | 10,460 | 20,334 | 20,123
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3,388 | 2,634 | 6,672 | 4,903
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 178 | 111 | 323 | 190
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 151 | 97 | 279 | 171
Total Pharmaceutical segment sales | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 33 | 121 | 76 | 237
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 656 | 886 | 1,753 | 1,724
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 378 | 675 | 813 | 1,171
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 168 | 172 | 391 | 383
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 117 | 170 | 373 | 355
Total Pharmaceutical segment sales | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 28 | 58 | 88 | 105
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 224 | 278 | 524 | 533
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 193 | 168 | 383
Total Pharmaceutical segment sales | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 38 | 123 | 70
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 71 | 115 | 130
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 78 | 108 | 150
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 67 | 98 | 129
Total Pharmaceutical segment sales | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 32 | 67 | 78 | 155
Total Pharmaceutical segment sales | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 32 | 27 | 69 | 53
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 191 | 214 | 406 | 422
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 98 | 160 | 221
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 84 | 76 | 163 | 143
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 196 | 247 | 441 | 502
Total Pharmaceutical segment sales | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 108 | 94 | 221
Total Pharmaceutical segment sales | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 137 | 156 | 282 | 296
Total Pharmaceutical segment sales | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 76 | 92 | 174
Total Pharmaceutical segment sales | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 115 | 92 | 238 | 186
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Adempas (2) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 79 | 51 | 133 | 94
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 57 | 53 | 113 | 100
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 854 | 908 | 1,628 | 1,732
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 490 | 533 | 993 | 1,063
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 132 | 183 | 326 | 382
Total Pharmaceutical segment sales | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 240 | 126 | 459
Total Pharmaceutical segment sales | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 160 | 255 | 352
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 109 | 200 | 213
Total Pharmaceutical segment sales | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 75 | 135 | 149
Total Pharmaceutical segment sales | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 72 | 120 | 168
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 44 | 63 | 85 | 121
Total Pharmaceutical segment sales | Operating Segments | Other pharmaceutical (3) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,103 | 1,203 | 2,293 | 2,283
Total Pharmaceutical segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,270 | 4,807 | 8,984 | 9,022
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,043 | 1,498 | 3,949 | 2,782
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 105 | 66 | 190 | 116
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 54 | 188 | 104
Total Pharmaceutical segment sales | United States | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6 | 67 | 11 | 130
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 168 | 456 | 629 | 818
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 263 | 500 | 596 | 843
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 104 | 241 | 258
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 21 | 123 | 203 | 248
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 17 | 38 | 47 | 67
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 107 | 129 | 250 | 248
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6 | 100 | 14 | 191
Total Pharmaceutical segment sales | United States | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 28 | 19 | 55 | 37
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | 0 | 1 | 1
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 18 | 6 | 31
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (2) | 3 | 1 | 4
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10 | 22 | 25 | 64
Total Pharmaceutical segment sales | United States | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 17 | 13 | 37 | 25
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 22 | 21 | 49 | 45
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 76 | 94 | 151 | 202
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15 | 39 | 33 | 72
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (1) | 6 | (4) | 6
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | 3 | 5 | 6
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Adempas (2) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 49 | 122 | 89
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 413 | 471 | 768 | 855
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 143 | 166 | 256 | 333
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 87 | 136 | 237 | 285
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 206 | 61 | 391
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4 | 8 | 9 | 13
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4 | 6 | 12 | 10
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4 | (1) | 10 | (2)
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 20 | 24 | 40 | 53
Total Pharmaceutical segment sales | United States | Operating Segments | Other pharmaceutical (3) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 385 | 369 | 792 | 697
Total Pharmaceutical segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,409 | 5,653 | 11,350 | 11,101
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,345 | 1,136 | 2,722 | 2,121
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 45 | 133 | 74
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 43 | 91 | 67
Total Pharmaceutical segment sales | International | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 27 | 54 | 65 | 107
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 488 | 430 | 1,124 | 906
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 115 | 174 | 217 | 328
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 68 | 150 | 125
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 96 | 47 | 170 | 107
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 11 | 20 | 41 | 39
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 117 | 149 | 274 | 285
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 67 | 93 | 154 | 192
Total Pharmaceutical segment sales | International | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 18 | 68 | 33
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 70 | 114 | 129
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 60 | 102 | 118
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 64 | 98 | 125
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 21 | 45 | 53 | 91
Total Pharmaceutical segment sales | International | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15 | 14 | 32 | 28
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 191 | 214 | 406 | 422
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 98 | 160 | 221
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 61 | 55 | 114 | 98
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 120 | 153 | 290 | 300
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 24 | 68 | 62 | 149
Total Pharmaceutical segment sales | International | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 138 | 150 | 285 | 290
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 37 | 73 | 86 | 167
Total Pharmaceutical segment sales | International | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 115 | 92 | 238 | 186
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Adempas (2) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6 | 2 | 11 | 5
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 57 | 53 | 113 | 100
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 441 | 437 | 860 | 877
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 348 | 366 | 737 | 730
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 44 | 48 | 90 | 98
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 28 | 34 | 65 | 68
Total Pharmaceutical segment sales | International | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 96 | 153 | 246 | 338
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 94 | 103 | 189 | 202
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 75 | 135 | 149
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 73 | 110 | 170
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 24 | 39 | 45 | 67
Total Pharmaceutical segment sales | International | Operating Segments | Other pharmaceutical (3) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 720 | 837 | 1,500 | 1,589
Total Animal Health segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,101 | 1,124 | 2,314 | 2,149
Total Animal Health segment sales | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 648 | 671 | 1,386 | 1,282
Total Animal Health segment sales | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 453 | 453 | 928 | 867
Total Animal Health segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 342 | 335 | 726 | 628
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 122 | 145 | 284 | 261
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 220 | 190 | 442 | 367
Total Animal Health segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 759 | 789 | 1,588 | 1,521
Total Animal Health segment sales | International | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 526 | 526 | 1,102 | 1,021
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 233 | 263 | 486 | 500
Other segment sales (4) | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 48 | 23 | 87
Other segment sales (4) | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 47 | 23 | 86
Other segment sales (4) | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |